Application 021588

Type
NDA
Sponsor
NOVARTIS

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001GLEEVECIMATINIB MESYLATETABLET;ORALEQ 100MG BASEYesNo
002GLEEVECIMATINIB MESYLATETABLET;ORALEQ 400MG BASEYesYes

NDC Listings For This Application#

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
0078-0401Gleevecimatinib mesylateNovartis Pharmaceuticals CorporationNDACurrent
0078-0401Gleevecimatinib mesylateNovartis Pharmaceuticals CorporationNDACurrent
0078-0401Gleevecimatinib mesylateNovartis Pharmaceuticals CorporationNDACurrent
0078-0401Gleevecimatinib mesylateNovartis Pharmaceuticals CorporationNDACurrent
0078-0401Gleevecimatinib mesylateNovartis Pharmaceuticals CorporationNDACurrent
0078-0401Gleevecimatinib mesylateNovartis Pharmaceuticals CorporationNDACurrent
0078-0401Gleevecimatinib mesylateNovartis Pharmaceuticals CorporationNDACurrent
0078-0401Gleevecimatinib mesylateNovartis Pharmaceuticals CorporationNDACurrent
0078-0401Gleevecimatinib mesylateNovartis Pharmaceuticals CorporationNDACurrent
0078-0649Gleevecimatinib mesylateNovartis Pharmaceuticals CorporationNDACurrent
0078-0649Gleevecimatinib mesylateNovartis Pharmaceuticals CorporationNDACurrent
0078-0649Gleevecimatinib mesylateNovartis Pharmaceuticals CorporationNDACurrent
0078-0649Gleevecimatinib mesylateNovartis Pharmaceuticals CorporationNDACurrent
0078-0649Gleevecimatinib mesylateNovartis Pharmaceuticals CorporationNDACurrent
0078-0649Gleevecimatinib mesylateNovartis Pharmaceuticals CorporationNDACurrent
0078-0649Gleevecimatinib mesylateNovartis Pharmaceuticals CorporationNDACurrent
0078-0649Gleevecimatinib mesylateNovartis Pharmaceuticals CorporationNDACurrent
0078-0649Gleevecimatinib mesylateNovartis Pharmaceuticals CorporationNDACurrent
66828-0030Gleevecimatinib mesylateNovartis Pharma Produktions GmbHNDACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
84783SUPPL 2026-01-20
84758SUPPL 2026-01-15
77776SUPPL 2024-03-11
77773SUPPL 2024-03-11
71855SUPPL2022-08-22
71854SUPPL2022-08-22
70610SUPPL2022-03-25
64261SUPPL2020-08-11
64260SUPPL2020-08-11
64255SUPPL2020-08-11
64254SUPPL2020-08-11
55319SUPPL2018-08-24
55270SUPPL2018-08-22
49930SUPPL2017-10-03
49920SUPPL2017-10-03
49698SUPPL2017-09-08
49680SUPPL2017-09-07
48142SUPPL2017-04-27
48097SUPPL2017-04-25
45472SUPPL2016-10-04
45425SUPPL2016-09-29
45170SUPPL2016-08-25
45169SUPPL2016-08-25
45064SUPPL2016-08-25
45063SUPPL2016-08-25
21747SUPPL2015-05-26
15838SUPPL2015-02-03
28198SUPPL2015-02-02
37293SUPPL2014-05-28
5804SUPPL2014-05-22
37292SUPPL2013-10-31
5803SUPPL2013-10-31
37291SUPPL2013-02-26
5802SUPPL2013-02-25
37290SUPPL2013-01-30
5801SUPPL2013-01-30
5800SUPPL2012-02-03
15837SUPPL2012-01-31
28197SUPPL2011-04-06
5799SUPPL2011-04-06
37289SUPPL2011-04-01
37288SUPPL2011-04-01
15836SUPPL2009-06-05
28195SUPPL2009-06-02
5798SUPPL2009-06-02
28196SUPPL2009-02-13
37287SUPPL2009-02-12
5797SUPPL2008-12-29
28194SUPPL2008-10-01
28193SUPPL2008-10-01
5795SUPPL2008-10-01
37286SUPPL2008-09-26
37285SUPPL2008-09-26
37284SUPPL2008-09-26
5796SUPPL2008-05-05
28192SUPPL2007-09-25
37283SUPPL2007-09-19
37279SUPPL2006-11-06
5790SUPPL2006-11-06
37282SUPPL2006-10-23
37281SUPPL2006-10-23
28191SUPPL2006-10-23
28189SUPPL2006-10-23
15834SUPPL2006-10-23
15833SUPPL2006-10-23
15832SUPPL2006-10-23
5794SUPPL2006-10-23
5793SUPPL2006-10-23
5792SUPPL2006-10-23
42224SUPPL2006-10-19
42223SUPPL2006-10-19
42222SUPPL2006-10-19
21749SUPPL2006-10-19
21748SUPPL2006-10-19
28190SUPPL2006-10-02
15835SUPPL2006-09-28
42219ORIG2006-06-07
5791SUPPL2006-06-02
37280SUPPL2006-06-01
15831SUPPL2005-10-25
5789SUPPL2005-10-25
28188SUPPL2005-05-20
5788SUPPL2005-05-20
42221SUPPL2005-04-08
28187SUPPL2005-03-18
15830SUPPL2005-03-18
42220SUPPL2004-08-09
37278SUPPL2004-06-25
28186SUPPL2004-06-25
5787SUPPL2003-12-22
44136ORIG2003-12-09
15829SUPPL2003-12-08
5786SUPPL2003-06-08
28185ORIG2003-05-29
15828SUPPL2003-05-20
15827ORIG2003-04-28
51978SUPPL1900-01-01
51977SUPPL1900-01-01
51976SUPPL1900-01-01
51975SUPPL1900-01-01